Advertisement

Index by author

November 01, 1985; Volume 28,Issue 5

B

  1. Berger, F G

    1. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells.
      S H Berger, C H Jenh, L F Johnson and F G Berger
      Molecular Pharmacology November 1985, 28 (5) 461-467;

  2. Berger, S H

    1. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells.
      S H Berger, C H Jenh, L F Johnson and F G Berger
      Molecular Pharmacology November 1985, 28 (5) 461-467;

  3. Brasier, R S

    1. Agonist and antagonist binding to alpha 2-adrenergic receptors in purified membranes from human platelets. Implications of receptor-inhibitory nucleotide-binding protein stoichiometry.
      R R Neubig, R D Gantzos and R S Brasier
      Molecular Pharmacology November 1985, 28 (5) 475-486;

  4. Burch, M

    1. Structure-activity relationships for the irreversible blockade of nicotinic receptor agonist sites by lophotoxin and congeneric diterpene lactones.
      P Culver, M Burch, C Potenza, L Wasserman, W Fenical and P Taylor
      Molecular Pharmacology November 1985, 28 (5) 436-444;

  5. Bylund, D B

    1. Alpha 2-adrenergic receptors in the human cell line, HT29. Characterization with the full agonist radioligand [3H]UK-14,304 and inhibition of adenylate cyclase.
      J T Turner, C Ray-Prenger and D B Bylund
      Molecular Pharmacology November 1985, 28 (5) 422-430;

C

  1. Culver, P

    1. Structure-activity relationships for the irreversible blockade of nicotinic receptor agonist sites by lophotoxin and congeneric diterpene lactones.
      P Culver, M Burch, C Potenza, L Wasserman, W Fenical and P Taylor
      Molecular Pharmacology November 1985, 28 (5) 436-444;

  2. Cysyk, R L

    1. Inhibition of uridine kinase and the salvage of uridine by modified pyrimidine nucleosides.
      J D Moyer, J M Karle, N Malinowski, V E Marquez, M A Salam, L Malspeis and R L Cysyk
      Molecular Pharmacology November 1985, 28 (5) 454-460;

D

  1. Davies, H W

    1. Immunochemical evidence of trifluoroacetylated cytochrome P-450 in the liver of halothane-treated rats.
      H Satoh, J R Gillette, H W Davies, R D Schulick and L R Pohl
      Molecular Pharmacology November 1985, 28 (5) 468-474;

  2. Drendel, W B

    1. Structure-activity relationship of bispyridyloxybenzene for induction of mouse hepatic aminopyrine N-demethylase activity. Chemical, biological, and X-ray crystallographic studies.
      A S Kende, F H Ebetino, W B Drendel, M Sundaralingam, E Glover and A Poland
      Molecular Pharmacology November 1985, 28 (5) 445-453;

E

  1. Ebetino, F H

    1. Structure-activity relationship of bispyridyloxybenzene for induction of mouse hepatic aminopyrine N-demethylase activity. Chemical, biological, and X-ray crystallographic studies.
      A S Kende, F H Ebetino, W B Drendel, M Sundaralingam, E Glover and A Poland
      Molecular Pharmacology November 1985, 28 (5) 445-453;

  2. Ehlert, F J

    1. The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium.
      F J Ehlert
      Molecular Pharmacology November 1985, 28 (5) 410-421;

F

  1. Fenical, W

    1. Structure-activity relationships for the irreversible blockade of nicotinic receptor agonist sites by lophotoxin and congeneric diterpene lactones.
      P Culver, M Burch, C Potenza, L Wasserman, W Fenical and P Taylor
      Molecular Pharmacology November 1985, 28 (5) 436-444;

G

  1. Gantzos, R D

    1. Agonist and antagonist binding to alpha 2-adrenergic receptors in purified membranes from human platelets. Implications of receptor-inhibitory nucleotide-binding protein stoichiometry.
      R R Neubig, R D Gantzos and R S Brasier
      Molecular Pharmacology November 1985, 28 (5) 475-486;

  2. George, S R

    1. Dopamine D2 receptor binding sites for agonists. A tetrahedral model.
      P Seeman, M Watanabe, D Grigoriadis, J L Tedesco, S R George, U Svensson, J L Nilsson and J L Neumeyer
      Molecular Pharmacology November 1985, 28 (5) 391-399;

  3. Gillette, J R

    1. Immunochemical evidence of trifluoroacetylated cytochrome P-450 in the liver of halothane-treated rats.
      H Satoh, J R Gillette, H W Davies, R D Schulick and L R Pohl
      Molecular Pharmacology November 1985, 28 (5) 468-474;

  4. Glover, E

    1. Structure-activity relationship of bispyridyloxybenzene for induction of mouse hepatic aminopyrine N-demethylase activity. Chemical, biological, and X-ray crystallographic studies.
      A S Kende, F H Ebetino, W B Drendel, M Sundaralingam, E Glover and A Poland
      Molecular Pharmacology November 1985, 28 (5) 445-453;

  5. Grigoriadis, D

    1. Dopamine D2 receptor binding sites for agonists. A tetrahedral model.
      P Seeman, M Watanabe, D Grigoriadis, J L Tedesco, S R George, U Svensson, J L Nilsson and J L Neumeyer
      Molecular Pharmacology November 1985, 28 (5) 391-399;

H

  1. Henley, J M

    1. Epinephrine-stimulated maintained rubidium efflux from guinea pig hepatocytes may involve alpha 1- and alpha 2-adrenoceptors.
      J M Henley
      Molecular Pharmacology November 1985, 28 (5) 431-435;

  2. Hosey, M M

    1. Agonist interactions with cardiac muscarinic receptors. Effects of Mg2+, guanine nucleotides, and monovalent cations.
      K K McMahon and M M Hosey
      Molecular Pharmacology November 1985, 28 (5) 400-409;

J

  1. Jenh, C H

    1. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells.
      S H Berger, C H Jenh, L F Johnson and F G Berger
      Molecular Pharmacology November 1985, 28 (5) 461-467;

  2. Johnson, L F

    1. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells.
      S H Berger, C H Jenh, L F Johnson and F G Berger
      Molecular Pharmacology November 1985, 28 (5) 461-467;

K

  1. Karle, J M

    1. Inhibition of uridine kinase and the salvage of uridine by modified pyrimidine nucleosides.
      J D Moyer, J M Karle, N Malinowski, V E Marquez, M A Salam, L Malspeis and R L Cysyk
      Molecular Pharmacology November 1985, 28 (5) 454-460;

  2. Kende, A S

    1. Structure-activity relationship of bispyridyloxybenzene for induction of mouse hepatic aminopyrine N-demethylase activity. Chemical, biological, and X-ray crystallographic studies.
      A S Kende, F H Ebetino, W B Drendel, M Sundaralingam, E Glover and A Poland
      Molecular Pharmacology November 1985, 28 (5) 445-453;

M

  1. Malinowski, N

    1. Inhibition of uridine kinase and the salvage of uridine by modified pyrimidine nucleosides.
      J D Moyer, J M Karle, N Malinowski, V E Marquez, M A Salam, L Malspeis and R L Cysyk
      Molecular Pharmacology November 1985, 28 (5) 454-460;

  2. Malspeis, L

    1. Inhibition of uridine kinase and the salvage of uridine by modified pyrimidine nucleosides.
      J D Moyer, J M Karle, N Malinowski, V E Marquez, M A Salam, L Malspeis and R L Cysyk
      Molecular Pharmacology November 1985, 28 (5) 454-460;

  3. Marquez, V E

    1. Inhibition of uridine kinase and the salvage of uridine by modified pyrimidine nucleosides.
      J D Moyer, J M Karle, N Malinowski, V E Marquez, M A Salam, L Malspeis and R L Cysyk
      Molecular Pharmacology November 1985, 28 (5) 454-460;

  4. McMahon, K K

    1. Agonist interactions with cardiac muscarinic receptors. Effects of Mg2+, guanine nucleotides, and monovalent cations.
      K K McMahon and M M Hosey
      Molecular Pharmacology November 1985, 28 (5) 400-409;

  5. Moyer, J D

    1. Inhibition of uridine kinase and the salvage of uridine by modified pyrimidine nucleosides.
      J D Moyer, J M Karle, N Malinowski, V E Marquez, M A Salam, L Malspeis and R L Cysyk
      Molecular Pharmacology November 1985, 28 (5) 454-460;

N

  1. Neubig, R R

    1. Agonist and antagonist binding to alpha 2-adrenergic receptors in purified membranes from human platelets. Implications of receptor-inhibitory nucleotide-binding protein stoichiometry.
      R R Neubig, R D Gantzos and R S Brasier
      Molecular Pharmacology November 1985, 28 (5) 475-486;

  2. Neumeyer, J L

    1. Dopamine D2 receptor binding sites for agonists. A tetrahedral model.
      P Seeman, M Watanabe, D Grigoriadis, J L Tedesco, S R George, U Svensson, J L Nilsson and J L Neumeyer
      Molecular Pharmacology November 1985, 28 (5) 391-399;

  3. Nilsson, J L

    1. Dopamine D2 receptor binding sites for agonists. A tetrahedral model.
      P Seeman, M Watanabe, D Grigoriadis, J L Tedesco, S R George, U Svensson, J L Nilsson and J L Neumeyer
      Molecular Pharmacology November 1985, 28 (5) 391-399;

P

  1. Pohl, L R

    1. Immunochemical evidence of trifluoroacetylated cytochrome P-450 in the liver of halothane-treated rats.
      H Satoh, J R Gillette, H W Davies, R D Schulick and L R Pohl
      Molecular Pharmacology November 1985, 28 (5) 468-474;

  2. Poland, A

    1. Structure-activity relationship of bispyridyloxybenzene for induction of mouse hepatic aminopyrine N-demethylase activity. Chemical, biological, and X-ray crystallographic studies.
      A S Kende, F H Ebetino, W B Drendel, M Sundaralingam, E Glover and A Poland
      Molecular Pharmacology November 1985, 28 (5) 445-453;

  3. Potenza, C

    1. Structure-activity relationships for the irreversible blockade of nicotinic receptor agonist sites by lophotoxin and congeneric diterpene lactones.
      P Culver, M Burch, C Potenza, L Wasserman, W Fenical and P Taylor
      Molecular Pharmacology November 1985, 28 (5) 436-444;

R

  1. Ray-Prenger, C

    1. Alpha 2-adrenergic receptors in the human cell line, HT29. Characterization with the full agonist radioligand [3H]UK-14,304 and inhibition of adenylate cyclase.
      J T Turner, C Ray-Prenger and D B Bylund
      Molecular Pharmacology November 1985, 28 (5) 422-430;

S

  1. Salam, M A

    1. Inhibition of uridine kinase and the salvage of uridine by modified pyrimidine nucleosides.
      J D Moyer, J M Karle, N Malinowski, V E Marquez, M A Salam, L Malspeis and R L Cysyk
      Molecular Pharmacology November 1985, 28 (5) 454-460;

  2. Satoh, H

    1. Immunochemical evidence of trifluoroacetylated cytochrome P-450 in the liver of halothane-treated rats.
      H Satoh, J R Gillette, H W Davies, R D Schulick and L R Pohl
      Molecular Pharmacology November 1985, 28 (5) 468-474;

  3. Schulick, R D

    1. Immunochemical evidence of trifluoroacetylated cytochrome P-450 in the liver of halothane-treated rats.
      H Satoh, J R Gillette, H W Davies, R D Schulick and L R Pohl
      Molecular Pharmacology November 1985, 28 (5) 468-474;

  4. Seeman, P

    1. Dopamine D2 receptor binding sites for agonists. A tetrahedral model.
      P Seeman, M Watanabe, D Grigoriadis, J L Tedesco, S R George, U Svensson, J L Nilsson and J L Neumeyer
      Molecular Pharmacology November 1985, 28 (5) 391-399;

  5. Sundaralingam, M

    1. Structure-activity relationship of bispyridyloxybenzene for induction of mouse hepatic aminopyrine N-demethylase activity. Chemical, biological, and X-ray crystallographic studies.
      A S Kende, F H Ebetino, W B Drendel, M Sundaralingam, E Glover and A Poland
      Molecular Pharmacology November 1985, 28 (5) 445-453;

  6. Svensson, U

    1. Dopamine D2 receptor binding sites for agonists. A tetrahedral model.
      P Seeman, M Watanabe, D Grigoriadis, J L Tedesco, S R George, U Svensson, J L Nilsson and J L Neumeyer
      Molecular Pharmacology November 1985, 28 (5) 391-399;

T

  1. Taylor, P

    1. Structure-activity relationships for the irreversible blockade of nicotinic receptor agonist sites by lophotoxin and congeneric diterpene lactones.
      P Culver, M Burch, C Potenza, L Wasserman, W Fenical and P Taylor
      Molecular Pharmacology November 1985, 28 (5) 436-444;

  2. Tedesco, J L

    1. Dopamine D2 receptor binding sites for agonists. A tetrahedral model.
      P Seeman, M Watanabe, D Grigoriadis, J L Tedesco, S R George, U Svensson, J L Nilsson and J L Neumeyer
      Molecular Pharmacology November 1985, 28 (5) 391-399;

  3. Turner, J T

    1. Alpha 2-adrenergic receptors in the human cell line, HT29. Characterization with the full agonist radioligand [3H]UK-14,304 and inhibition of adenylate cyclase.
      J T Turner, C Ray-Prenger and D B Bylund
      Molecular Pharmacology November 1985, 28 (5) 422-430;

W

  1. Wasserman, L

    1. Structure-activity relationships for the irreversible blockade of nicotinic receptor agonist sites by lophotoxin and congeneric diterpene lactones.
      P Culver, M Burch, C Potenza, L Wasserman, W Fenical and P Taylor
      Molecular Pharmacology November 1985, 28 (5) 436-444;

  2. Watanabe, M

    1. Dopamine D2 receptor binding sites for agonists. A tetrahedral model.
      P Seeman, M Watanabe, D Grigoriadis, J L Tedesco, S R George, U Svensson, J L Nilsson and J L Neumeyer
      Molecular Pharmacology November 1985, 28 (5) 391-399;
Back to top

In this issue

Advertisement